Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9567007 | 1.00 | TDP1 (0.57) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL9485459 | 1.00 | TDP1 (0.57) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL8576168 | 1.00 | TDP1 (0.57) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL9699198 | 1.00 | TDP1 (0.57) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL4473332 | 1.00 | TDP1 (0.57) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL4177303 | 0.98 | TDP1 (0.59) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL12495594 | 0.91 | L3MBTL1 (0.50) | TDP1L3MBTL1PTGS2CYP3A4KDM4E | |
| SCHEMBL27563659 | 0.82 | TDP1 (0.57) | TDP1L3MBTL1PTGS2ESR1ADRA2A | |
| SCHEMBL22267934 | 0.81 | SIGMAR1 (0.56) | TDP1L3MBTL1ALDH1A1LMNACHRM2 | |
| SCHEMBL13527238 | 0.81 | HSD17B10 (0.56) | TDP1L3MBTL1PTGS2ESR1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110257379-B | Oligonucleotides for treating patients with muscular dystrophy | 马林生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-3608407-A1 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | BioMarin Technologies B.V. (NL) | 2020-02-12 | — | — | EP | disclosed |
| CN-110257379-A | For treating the oligonucleotides of muscular dystrophy patient | 马林生物科技有限公司 | 2019-09-20 | — | — | CN | disclosed |
| EP-2870246-B1 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | BIOMARIN TECH BV (NL) | 2019-09-11 | — | — | EP | disclosed |
| CN-104603271-B | Oligonucleotides for treating patients with muscular dystrophy | 马林生物科技有限公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20170050941-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-23 | — | — | US | disclosed |
| US-20150191725-A1 | Oligonucleotide for the Treatment of Muscular Dystrophy Patients | BIOMARIN TECHNOLOGIES B.V. (NL) | 2015-07-09 | — | — | US | disclosed |
| EP-2870246-A2 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | Prosensa Technologies B.V. (NL) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014007620-A2 | OLIGONUCLEOTIDE FOR THE TREATMENT OF MUSCULAR DYSTROPHY PATIENTS | PROSENSA TECHNOLOGIES B.V. (NL) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050941-A1 | NOVEL MODULATORS OF SPHINGOSINE PHOSPHATE RECEPTORS | S1PR1, S1PR3, S1PR2 | TDP1 3014/4885L3MBTL1 3405/4885PTGS2 2898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.